Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Widespread Zika screens not cost effective

Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

Key clinical point: Individually screening all blood donations for Zika virus was low yield and costly.

Major finding: Testing confirmed only 8 authentic cases and cost nearly $42 million over 15 months.

Study details: Screening and confirmatory testing of 4,325,889 donations of blood in the United States during 2016-2017.

Disclosures: American Red Cross and Grifols Diagnostic Solutions provided funding. Grifols makes a test used in the study. Dr. Saá disclosed research support from Grifols but had no other conflicts of interest.

Source: Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

Citation:

Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

Commentary:

Despite these findings, it would be premature to stop testing U.S. blood donations for Zika virus, wrote Evan M. Bloch, MBChB; Paul M. Ness, MD; Aaron A.R. Tobian, MD, PhD; and Jeremy Sugarman, MD, MPH, in an editorial accompanying the study.

Nonetheless, “actual and perceived risks to the blood supply seem to be conflated,” the experts wrote. They noted that the United States currently has no active areas of Zika virus transmission and that confirmed mosquito-borne, locally acquired infections fell from 226 in 2016 to two the following year.

There is no historical precedent for ending a policy of testing blood donations for pathogens, they added. Consequently, ending widespread screening “may actually prove to be far more challenging than the decision to start.” For now, a precautionary, risk-based approach should entail “continuous review” of screening policies and “reassessment as new data emerge.”

The editorialists are with Johns Hopkins University and Johns Hopkins University’s Bergman Institute of Bioethics, both in Baltimore. They reported having no relevant conflicts of interest. These comments are from their editorial (New Engl J Med. 2018;378:19:1837-41).

This Week's Must Reads

FDA postmarketing requirements, Nabhan C et al. JAMA Oncol. 2018 May 10. doi:10.1001/jamaoncol.2018.0610.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.

Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.

Methotrexate or nelarabine plus chemo in pediatric T-ALL or T-L, Dunsmore KP et al. ASCO 2018, Abstract 10500.

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Must Reads in Transfusion Medicine

Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.

Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

Transfusions don't factor in rheumatoid arthritis transmission, Just SA et al. Ann Rheum Dis. 2018 Mar 1. doi: 10.1136/annrheumdis-2017-212844.

Cochrane Evaluates Red Blood Cell Transfusion Policies, Cochrane Database Syst Rev; 2017 Jan 27; Estcourt, et al

Comparison of Red Blood Cell Transfusion Utilization, J Thromb Haemost; ePub 2016 Oct 28; Belk, et al